

8/15/02

STM Search History

=> s (adjuvant or (metal### (a) salt) or (aluminum (a) (phosphate or hydroxide))) (s)
(adsorb## and (immunostimulant or antigen))

=> s (adjuvant or (metal### (a) salt) or (aluminum (a) (phosphate or hydroxide))) (s)
(immunostimulant and antigen)

s (adjuvant or (metal### (a) salt) or (aluminum (a) (phosphate or hydroxide)))

L1 QUE (ADJUVANT OR (METAL### (A) SALT) OR (ALUMINUM (A) (PHOSPHATE OR HYDROX
IDE)))

L2 QUE (ANTIGEN (S) IMMUNOSTIMULANT)

L3 QUE L1 AND L2

1 817 CAPLUS

F2 185 USPATFULL

F3 108 DGENE

F4 60 WPIDS

F5 60 WPINDEX

F6 56 BIOSIS

F7 53 MEDLINE

F8 28 EMBASE

F9 26 NLDB

F10 24 CANCERLIT

F11 23 TOXCENTER

F12 22 BIOTECHABS

F13 22 BIOTECHDS

F14 22 PROMT

F15 16 SCISEARCH

F16 15 BIOTECHNO

F17 15 INVESTEXT

F18 13 ADISINSIGHT

F19 13 LIFESCI

F20 13 VETU

F21 12 IFIPAT

F22 10 DRUGU

L4 4173 (ADJUVANT OR (METAL### (A) SALT) OR (ALUMINUM (A) (PHOSPHATE OR
HYDROXIDE))) AND ANTIGEN AND IMMUNOSTIMULANT

L5 3890 DUP REM L4 (283 DUPLICATES REMOVED)

L6 248 L5 AND (MPL OR (MONOPHOSPHORYL (A) LIPID))

L7 241 L6 AND (IMMUNOSTIMULANT OR MPL OR LIPID) (S) (ADJUVANT OR METAL
OR ALUMINUM OR ALUM)

L8 11 L6 AND (IMMUNOSTIMULANT OR MPL OR LIPID) (S) (ADJUVANT OR METAL
OR ALUMINUM OR ALUM) (S) ADSORB###

L9 3879 L5 NOT L8

L10 1888 L5 AND (IMMUNOSTIMULANT (S) ADJUVANT) AND (ANTIGEN (S) ADJUVANT

L11 2225 L5 AND (IMMUNOSTIMULANT (S) ADJUVANT OR ALUMINUM OR ALUM) AND
(ANTIGEN (S) ADJUVANT OR ALUMINUM OR ALUM)

L12 355 L11 AND HEPATITIS

L13 76 L12 AND SAPONIN

L14 160 L10 AND L6

L15 114 L14 NOT L13

FILE 'CAPLUS, USPATFULL, DGENE, WPINDEX, BIOSIS, MEDLINE, EMBASE,
SCISEARCH, BIOTECHNO' ENTERED AT 15:19:05 ON 15 AUG 2002

L4	4173 S (ADJUVANT OR (METAL### (A) SALT) OR (ALUMINUM (A) (PHOSPHATE
L5	3890 DUP REM L4 (283 DUPLICATES REMOVED)
L6	248 S L5 AND (MPL OR (MONOPHOSPHORYL (A) LIPID))
L7	241 S L6 AND (IMMUNOSTIMULANT OR MPL OR LIPID) (S) (ADJUVANT OR ME
L8	11 S L6 AND (IMMUNOSTIMULANT OR MPL OR LIPID) (S) (ADJUVANT OR ME
L9	3879 S L5 NOT L8
L10	1888 S L5 AND (IMMUNOSTIMULANT (S) ADJUVANT) AND (ANTIGEN (S) ADJUV
L11	2225 S L5 AND (IMMUNOSTIMULANT (S) ADJUVANT OR ALUMINUM OR ALUM) AN
L12	355 S L11 AND HEPATITIS
L13	76 S L12 AND SAPONIN
L14	160 S L10 AND L6
L15	114 S L14 NOT L13

L8 ANSWER 5 OF 11 CAPLUS COPYRIGHT 2002 ACS
 AN 1990:597730 CAPLUS
 DN 113:197730
 TI Liposomes containing lipid A: a potent nontoxic **adjuvant** for a human malaria sporozoite vaccine
 AU Alving, Carl R.; Richards, Roberta L.
 CS Dep. Membr. Biochem., Walter Reed Army Inst. Res., Washington, DC, 20307-5100, USA
 SO Immunol. Lett. (1990), 25(1-3); 275-9
 CODEN: IMLED6; ISSN: 0165-2478
 DT Journal
 LA English
 AB Liposomes contg. lipid A were developed as **adjuvants** for inducing humoral immunity to synthetic **antigens** contg. repeat sequence epitopes from the circumsporozoite protein of Plasmodium falciparum. Preclin. studies demonstrated that liposomes contg. lipid A and encapsulated **antigen** could overcome immunosuppression obsd. with **antigen** alone. When liposomes contg. **lipid A** were **adsorbed** with **aluminum hydroxide** (**alum**), further stimulation of humoral immunity against encapsulated **antigen** was obsd. in animals. In the presence of huge doses of liposomal lipid A pyrogenicity was not obsd. and **adjuvant** activity was enhanced. A phase I human clin. trial was initiated utilizing a vaccine contg. a synthetic recombinant **antigen** and **monophosphoryl lipid A** in liposomes and nonliposomal alum as a further **adjuvant**. Preliminary results confirm that the vaccine lacks significant acute toxicity in humans and causes very strong specific humoral immunity against the appropriate epitopes of the target **antigen**.

L8 ANSWER 6 OF 11 USPATFULL
 AN 2001:233138 USPATFULL
 TI Vaccines
 IN Friede, Martin, Cardiff, CA, United States
 Garcon, Nathalie, Rixensart, Belgium
 PA SmithKline Beecham Biologicals s.a. (U.S. corporation)
 PI US 2001053365 A1 20011220
 AI US 2001-819464 A1 20010328 (9)
 RLI Continuation-in-part of Ser. No. US 1997-945450, filed on 12 Dec 1997, ABANDONED A 371 of International Ser. No. WO 1996-EP1464, filed on 1 Apr 1996, UNKNOWN A 371 of International Ser. No. US 1999-269383, filed on 2 Apr 1999, ABANDONED A 371 of International Ser. No. WO 1997-EP5578, filed on 30 Sep 1997, UNKNOWN
 PRAI GB 1995-8326 19950425
 GB 1996-910019 19960401
 GB 1996-20795 19961005
 DT Utility
 FS APPLICATION
 LREP GLAXOSMITHKLINE, Corporate Intellectual Property -UW2220, P. O. Box 1539, King of Prussia, PA, 19406-0939
 CLMN Number of Claims: 49
 ECL Exemplary Claim: 1
 DRWN 10 Drawing Page(s)
 LN.CNT 1397
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB The invention relates to a vaccine composition comprising an **antigen**, an immunologically active saponin fraction and a sterol.

L8 ANSWER 7 OF 11 USPATFULL
 AN 2000:21224 USPATFULL
 TI Herpes simplex vaccine comprising HSV glycoprotein GD and 3 deacylated **monophosphoryl lipid A**
 IN Francotte, Myriam, Rixensart, Belgium
 Prieels, Jean-Paul, Rixensart, Belgium
 Slaoui, Moncef, Rixensart, Belgium
 Garcon-Johnson, Nathalie Marie-Josephe Claude, Rixensart, Belgium
 PA Smithkline Beecham Biologicals, Rixensart, Belgium (non-U.S. corporation)
 PI US 6027730 20000222
 AI US 1994-303542 19940909 (8)
 RLI Continuation of Ser. No. US 119091
 PRAI GB 1991-5992 19910321
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Minnifield, Nita
 LREP Kerekes, Zoltan, Venetianer, Stephen, Kinzig, Charles M.
 CLMN Number of Claims: 11
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 1105
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel herpes simplex (HSV) vaccine formulations are provided. These comprise HSV glycoprotein gD or immunological fragments in conjunction with 3 Deacylated **monophosphoryl lipid A**.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 8 OF 11 USPATFULL
 AN 1998:78723 USPATFULL
 TI Vaccine compositions containing 3-O deacylated **monophosphoryl lipid A**
 IN Hauser, Pierre, Chaumont-Gistoux, Belgium
 Voet, Pierre, Izel, Belgium
 Slaoui, Moncef, Rixensart, Belgium
 Garcon-Johnson, Nathalie Marie-Josephe Claude, Wavre, Belgium
 Desmons, Pierre, Nivelles, Belgium
 PA SmithKline Beecham Biologicals (S.A.), Rixensart, Belgium (non-U.S. corporation)
 PI US 5776468 19980707
 WO 9421292 19940929
 AI US 1996-525638 19960212 (8)
 WO 1994-EP818 19940314
 19960212 PCT 371 date
 19960212 PCT 102(e) date
 PRAI GB 1993-6029 19930323
 GB 1994-3417 19940223
 DT Utility
 FS Granted
 EXNAM Primary Examiner: Knode, Marian C.; Assistant Examiner: Wortman, Donna C.
 CLMN Number of Claims: 53
 ECL Exemplary Claim: 1
 DRWN 1 Drawing Figure(s); 1 Drawing Page(s)
 LN.CNT 1493
 CAS INDEXING IS AVAILABLE FOR THIS PATENT.
 AB Novel vaccine compositions comprising small particles of 3-O-deacylated **monophosphoryl lipid A** are provided. In particular the particle size is below 120 nm. Such vaccine compositions have superior

immunological properties.

L14 ANSWER 72 OF 160 CAPLUS COPYRIGHT 2002 ACS
 AN 1997:621817 CAPLUS
 DN 127:276747
 TI Immunological **adjuvants** and their modes of action
 AU Allison, Anthony C.
 CS Dawa Corporation, Belmont, CA, 94002, USA
 SO Archivum Immunologiae et Therapiae Experimentalis (1997), 45(2-3), 141-147
 CODEN: AITEAT; ISSN: 0004-069X
 PB Zaklad Narodowy imienia Ossolinski
 DT Journal; General Review
 LA English
 AB A review with 44 refs. New **adjuvant** formulations contain a vehicle, which carries **antigens** to **antigen**-presenting cells. Examples of vehicles are liposomes, immune-stimulating complexes and microfluidized squalene-in-water emulsions. **Adjuvant** formulations may contain immunomodulators, which augment cytokine prodn., such as a synthetic muramyl dipeptide analog or **monophosphoryl lipid A**. In a primary cascade of cytokine prodn. at the site of **antigen + adjuvant** injection, TNF-.alpha. promotes the migration of dendritic cells (DC) to lymphoid tissues while GM-CSF accelerates the differentiation of DC into efficient presenters of **antigens** to T cells. **Adjuvants** also up-regulate a secondary cascade of cytokines in lymphoid tissues responding to antigenic stimulation: IL-12 augments the prodn. of IFN-.gamma., which favors the prodn. of antibodies of protective isotypes (IgG2a in the mouse). Thus **adjuvants** can regulate immune responses qual. as well as quant. **Adjuvant** formulations can also activate complement, generating C3d, which binds CD21 on follicular dendritic cells (FDC) and B cells. FDC targeting favors the generation of B lymphocyte memory, which is important for vaccination.

L14 ANSWER 67 OF 160 CAPLUS COPYRIGHT 2002 ACS
 AN 1998:239123 CAPLUS
 DN 128:307514
 TI Vaccines for infections and cancers
 IN Garcon, Nathalie; Friede, Martin
 PA Smithkline Beecham Biologicals S.A., Belg.; Garcon, Nathalie; Friede, Martin
 SO PCT Int. Appl., 31 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9815287	A1	19980416	WO 1997-EP5578	19970930
	W:	AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9747812	A1	19980505	AU 1997-47812	19970930
	AU 714930	B2	20000113		
	BR 9711853	A	19990824	BR 1997-11853	19970930
	EP 939650	A1	19990908	EP 1997-910430	19970930
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,			

IE, SI, FI

CN 1238696	A	19991215	CN 1997-180166	19970930
JP 2001501640	T2	20010206	JP 1998-517196	19970930
ZA 9708868	A	19990406	ZA 1997-8868	19971003
NO 9901524	A	19990329	NO 1999-1524	19990329
KR 2000048866	A	20000725	KR 1999-702874	19990402
US 2001053365	A1	20011220	US 2001-819464	20010328
PRAI GB 1996-20795	A	19961005		
GB 1995-8326	A	19950425		
EP 1996-910019	A	19960401		
WO 1996-EP1464	W	19960401		
WO 1997-EP5578	W	19970930		
US 1997-945450	B2	19971212		
US 1999-269383	W	19990402		

AB The invention relates to a vaccine compn. comprising an **antigen** and an **adjuvant** compn. for treating infections or cancer. The **adjuvant** compn. comprises alum, an immunol. active saponin fraction (e.g. QS21) assocd. with liposome contg. a phospholipid and a sterol (e.g. cholesterol), and 3-de-O-acylated **monophosphoryl lipid A**. The **antigen** is derived from human immunodeficiency virus, feline immunodeficiency virus, varicella zoster virus, herpes simplex virus type 1 and 2, human cytomegalovirus, hepatitis A, B, C or E, respiratory syncytial virus, human papilloma virus, influenza virus, Hib, meningitis virus, Salmonella, Neisseria, Borrelia, Chlamydia, Bordetella, Plasmodium, Toxoplasma, or cancer.

L14 ANSWER 65 OF 160 CAPLUS COPYRIGHT 2002 ACS

AN 1998:682150 CAPLUS

DN 129:293907

TI Aqueous immunologic **adjuvant** compositions of **monophosphoryl lipid A**

IN Crane, R. Thomas

PA Ribic Immunochem Research, Inc., USA

SO PCT Int. Appl., 29 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 3

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9843670	A2	19981008	WO 1998-US6528	19980401
	WO 9843670	A3	19981230		
	W:	AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GW, HU, ID, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
	RW:	GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG			
	AU 9869473	A1	19981022	AU 1998-69473	19980401
	AU 743114	B2	20020117		
	EP 971739	A2	20000119	EP 1998-915239	19980401
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI			
	BR 9811262	A	20001017	BR 1998-11262	19980401
	JP 2001526640	T2	20011218	JP 1998-542001	19980401
	NO 9904760	A	19991126	NO 1999-4760	19990930
PRAI	US 1997-831073	A	19970401		
	WO 1998-US6528	W	19980401		

AB An aq. **adjuvant** compn. comprising an attenuated lipid A deriv.

and a surfactant or surfactants enhances the immunol. response in a warm blooded animal to a protein **antigen**. Attenuated lipid A derivs. useful according to the subject invention include **monophosphoryl lipid A** and 3-O-deacylated **monophosphoryl lipid A**. A surfactant or mixts. of surfactants are dissolved in a solvent. 1,2-Dipalmitoyl-sn-glycero-3-phosphocholine is a preferred surfactant. The dissolved surfactant is added to an attenuated lipid A deriv. to obtain a mixt. The molar ratio of attenuated lipid A deriv. to surfactant in the mixt. is about 4:1. The solvent is evapd. and water is added to the resulting film. The suspension is sonicated in a 60 .degree.C water bath until it becomes clear. Animals administered the **adjuvant** formulation exhibited increased antibody responses to a given **antigen** as well as displayed enhanced lymphocyte proliferative and cytotoxic T-lymphocyte responses. Intranasal administration of the aq. **adjuvant** compn. and an **antigen** stimulates the prodn. of serum and mucosal secreted IgA.

L14 ANSWER 63 OF 160 CAPLUS COPYRIGHT 2002 ACS

AN 1999:9722 CAPLUS

DN 130:65240

TI **Adjuvant** compositions for vaccines

IN Boon, Thierry; Silla, Silvia; Uyttenhove, Catherine

PA Smithkline Beecham Biologicals S.A., Belg.

SO PCT Int. Appl., 28 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9857659	A1	19981223	WO 1998-EP3671	19980609
	W: CA, JP, US				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 977589	A1	20000209	EP 1998-939511	19980609
	R: BE, CH, DE, ES, FR, GB, IT, LI, NL				
	JP 2002504135	T2	20020205	JP 1999-503747	19980609
	US 6375945	B1	20020423	US 2000-445841	20000208
PRAI	GB 1997-12347	A	19970614		
	WO 1998-EP3671	W	19980609		

AB The present invention provides improved **adjuvant** compns. comprising QS21/3DMPL (3-O-deacylated **monophosphoryl lipid A**) and Interleukin 12. These find utility in a range of prophylactic and therapeutic vaccines, including cancer vaccines. Thus, vaccine comprising QS21, 3-O-deacylated **monophosphoryl lipid A**, phosphotidylcholine, cholesterol, and human tumor **antigen** peptide P815 or immune rejection major target **antigen** P815A was tested.

RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L14 ANSWER 61 OF 160 CAPLUS COPYRIGHT 2002 ACS

AN 1999:27854 CAPLUS

DN 130:94470

TI Improved methods for inducing an immune response

IN Warnier, Guy; Uyttenhove, Catherine; Boon-Falleur, Thierry

PA Ludwig Institute for Cancer Research, USA

SO PCT Int. Appl., 61 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 9858956	A2	19981230	WO 1998-US12894	19980619
	WO 9858956	A3	19990318		
	W: AU, CA, CN, JP, KR, NZ				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	AU 9879831	A1	19990104	AU 1998-79831	19980619
	ZA 9805460	A	19990126	ZA 1998-5460	19980623
PRAI	US 1997-880979		19970623		
	WO 1998-US12894		19980619		
AB	This invention relates to improved methods for modulating an immune response against an antigen using adenoviruses which express the antigen for priming immunization and antigen peptides for booster immunizations. The antigen is tumor antigen , allergen, allograft antigen , or autoimmune antigen , e.g. peptide derived from MAGE-1, MAGE-3, MAGE-6, BAGE, GAGE, RAGE, GnT-V, MUM-1, tyrosinase, and DAGE. Preferably the peptides are combined with QS21/ MPL adjuvant . Virus encoding the antigen is administered by injection (intradermally or s.c.). Kits for immunization are also provided.				